Resource Summary Report

Generated by dkNET on Aug 17, 2026

InVivoMAb anti-mouse CD20

RRID:AB_2894775
Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0356, RRID:AB_2894775)

Antibody Information

URL: http://antibodyregistry.org/AB_2894775

Proper Citation: (Bio X Cell Cat# BE0356, RRID:AB_2894775)

Target Antigen: CD20

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: in vivo Cell Specific Depletion, Western Blot

Antibody Name: InVivoMAb anti-mouse CD20

Description: This monoclonal targets CD20

Target Organism: mouse

Clone ID: clone MB20-11

Antibody ID: AB_2894775

Vendor: Bio X Cell

Catalog Number: BE0356

Alternative Catalog Numbers: BE0356-50MG, BE0356-25MG, BE0356-1MG, BE0356-100MG, BE0356-5MG

Record Creation Time: 20260114T193253+0000

Record Last Update: 20260623T051053+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMAb anti-mouse CD20.

No alerts have been found for InVivoMAb anti-mouse CD20.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Mao Y, et al. (2026) B cell deficiency limits exercise capacity by remodeling liver glutamate metabolism. Cell, 189(11), 3254.

Kirschstein E, et al. (2026) Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer. Cancer cell, 44(5), 1080.

Bosma DMT, et al. (2026) Requirements for development of T helper 1 and T follicular helper cells from a common precursor. Cell reports, 45(5), 117296.

Vuong L, et al. (2026) Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma. Cancer cell, 44(7), 1477.

Garg SK, et al. (2026) Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier. Cell reports, 45(3), 117050.

Ahn JJ, et al. (2025) Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity. Cell reports. Medicine, 6(8), 102257.

Osorio JC, et al. (2025) Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer cell.

Liu W, et al. (2024) An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure. Cell reports. Medicine, 5(3), 101448.

Yakkala C, et al. (2024) Cryoablation Does Not Significantly Contribute to Systemic Effector Immune Responses in a Poorly Immunogenic B16F10 Melanoma Model. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(18), 4190.

Cao S, et al. (2024) Glycosylation-modified antigens as a tolerance-inducing vaccine platform prevent anaphylaxis in a pre-clinical model of food allergy. Cell reports. Medicine, 5(1), 101346.

Chandra V, et al. (2024) Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation. Cancer cell, 42(1), 85.

Jin Y, et al. (2023) Engineer a double team of short-lived and glucose-sensing bacteria for cancer eradication. Cell reports. Medicine, 4(6), 101043.

Wattenberg MM, et al. (2023) Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1. Science immunology, 8(89), eadj5097.

Mirlekar B, et al. (2022) Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell reports. Medicine, 3(9), 100744.